Dr Lal Pathlabs Ltd Q4 FY26 Earnings Analysis
Published 16 Aug 2026 | Healthcare Services | Market Cap: ₹31.6K Cr
Price
₹1,916
Market Cap
₹31.6K Cr
P/E Ratio
56.3
Earnings Summary
Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually). The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery. - EBITDA margin is expected to be steady at around 27%-28% in FY27, with investments in infrastructure and organic growth balancing margin expansion. - Net profit margin (PAT margin) also expected to remain around 18%-19%, supported by margin stability despite ongoing investments. - EPS for FY26 was Rs.
📊 Revenue & Sales Performance
- →Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually).
- →Patient volume growth is expected to improve gradually, supported by expansion of labs and collection networks.
- →Recent quarter showed an 8.2% volume growth, but annualized growth (~5.3%) is a better indicator.
- →Growth is broad-based across regions, with sustained double-digit growth in Delhi NCR and improving growth in Suburban business.
- →Expansion in Tier 3 and Tier 4 geographies contributing positively without diluting realizations.
- →Increased focus on health packages and specialized testing, including the preventive healthcare brand Swasthfit (27% revenue contribution).
- →New labs and network additions (12-15 labs planned next year) will support volume growth.
- →No significant impact expected from GLP-1 launches in the short term.
- →Opportunity for margin improvement in certain geographies supports growth sustainability.
📈 Profitability & Margins
- →The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery.
- →EBITDA margin is expected to be steady at around 27%-28% in FY27, with investments in infrastructure and organic growth balancing margin expansion.
- →Net profit margin (PAT margin) also expected to remain around 18%-19%, supported by margin stability despite ongoing investments.
- →EPS for FY26 was Rs. 30.2 with growth over previous year Rs. 29.2; similar or modest growth expected as revenues grow.
- →Growth is driven by expanded lab and collection network, better service levels, and package offerings, with sustained improvements in patient volume growth.
- →The company is focusing on maintaining profitability while investing in new labs, precision diagnostics, and some inorganic expansion potential in Middle East markets.
🏗️ Capital Expenditure Plans
- →FY27 capex guidance is Rs. 100 crore - Rs. 120 crore.
- →Capex includes both maintenance and growth investments.
- →Growth capex planned for opening 12 to 15 new labs next year (14 labs added in current year).
- →Investments in a precision diagnostic lab with high-end complex testing equipment.
- →Incorporation of a subsidiary in Dubai as part of international expansion, considering both organic and inorganic opportunities including potential M&A in Middle East.
- →Some investments planned in radiology centers – slow and calibrated growth approach on radiology expansion, including integrated high-end radiology centers in Delhi NCR and possibly Tier 2 towns.
- →Investment in Sovaaka concept: currently one center launched; focus will be on stabilizing before further expansion.
- →Acquisition of Shahbazkers lab in Mumbai as a strategic asset addition targeting the micro-market.
💰 Fundraising & Capital Structure
📋 Order Book & Pipeline
Key Metrics
Frequently Asked Questions
What were Dr Lal Pathlabs Ltd Q4 FY26 results?
Revenue growth guidance for FY27 is early to mid-teens (around 13%-15% annually). The company guides for early to mid-teens revenue growth (13%-15%) in FY27, driven by broad-based growth including improved performance in Delhi NCR and Suburban business recovery. - EBITDA margin is expected to be steady at around 27%-28% in FY27, with investments in infrastructure and organic growth balancing margin expansion. - Net profit margin (PAT margin) also expected to remain around 18%-19%, supported by margin stability despite ongoing investments. - EPS for FY26 was Rs.
What is Dr Lal Pathlabs Ltd share price analysis?
Dr Lal Pathlabs Ltd currently shows a neutral. The stock trades at a P/E of 56.3 with a market cap of ₹31,635 Cr. Investors should review the full earnings analysis for detailed insights.
Is Dr Lal Pathlabs Ltd planning capital expenditure?
FY27 capex guidance is Rs.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.